Inactive Instrument

All News Luye Pharma Group Ltd Singapore S.E.

Equities

LUYE

BMG5722Z1014

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	Mar. 06	CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	Mar. 04	MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	Mar. 04	CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	Feb. 02	MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	Feb. 01	CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	Dec. 13	MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	Dec. 13	MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	Dec. 12	MT
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	Dec. 12	PU
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	Dec. 12	CI
Luye Pharma Group Ltd. Announces Board Changes	Dec. 06	CI
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	Dec. 05	AQ
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	Dec. 04	MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	Dec. 04	MT
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	Nov. 01	MT
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease	Oct. 31	PU
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	23-10-31	CI
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	23-10-09	MT
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	23-10-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Luye Pharma Group Ltd Singapore S.E.

Equities

LUYE

BMG5722Z1014

All News

Filters